DOSSIERS
Please find below our library of educational resources on ALK-positive non-small cell lung cancer
A VIDEO FROM THE INTERNATIONAL KEY OPINION LEADER PROF. DR. PETROS CHRISTOPOULOS ON THERAPEUTIC SEQUENCING IN ALK + NSCLC.
A video from the international key opinion leader prof. Dr. Petros christopoulos on therapeutic sequencing in ALK+ NSCLC.
VIDEO
RECORDING ROUND TABLE DISCUSSION ABOUT PATIENT-CENTERED CARE IN NSCLC WITH PROF CHRISTOPOULOS
The International Key Opinion Leader Prof. Dr. Petros Christopoulos presented key data about “The emerging new paradigm in early-stage NSCLC” and “Optimizing the management of ALK+ NSCLC patients”.
Both presentations were followed by a lively discussion with the three Belgian expert panelists, Dr. Mariana Brandao, Prof. Dr. Paul Germonpré and Prof. Nana Frank Aboubakar.
WEBINAR
PRODUITS
Please find below information about our products indicated for the management of ALK-positive non-small cell lung cancer
ALUNBRIG®
Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.